Navigation Links
NanoSmart™ Pharmaceuticals, Inc., Opens New Headquarters - Begins Development of New Drug Delivery Platform for Cancer

LAGUNA HILLS, Calif., Sept. 7, 2011 /PRNewswire/ -- NanoSmart™ Pharmaceuticals, Inc., a biopharmaceutical corporation developing novel cancer pharmaceuticals, has moved into its new corporate facility located in Laguna Hills, CA.  The facility provides the administrative and laboratory work space necessary to begin formal development of its initial product pipeline.

"Our new location gives us a physical presence in Orange County, California and allows us to move forward with our strategic development goals," said Dr. Henry Smith, CEO of the company.  "We are excited about the opportunity to develop our initial products and conduct formal, nonclinical studies leading towards our initial regulatory filings," said Dr. Smith.

About the technology:

NanoSmart™ is developing a patented, novel anti-tumor targeting platform based on fully-human autoimmune antibodies.  These antibodies target areas of necrosis found in many different types of cancer.  NanoSmart's drug delivery system represents a versatile platform technology with many advantages, including improved localization of cancer therapeutics leading to increased safety and efficacy.  By combining these antibodies with different cancer drugs, NanoSmart has the potential to develop a very large number of novel biopharmaceutical products.

NanoSmart™ Pharmaceuticals, Inc., is a privately-held company engaged in developing novel methods to treat cancer and other diseases.  The company is focused on using its patented tumor targeting antibodies to develop a variety of biopharmaceuticals to treat many different types of cancer.  This press release may contain forward-looking statements regarding future events.  There can be no assurance that such development efforts will succeed; or that the novel biopharmaceuticals will receive regulatory clearance or achieve commercial success.

For more information contact us at (949) 305-2020
E-mail us at
Investor Relations: (310) 951-3282

Please visit our website:

SOURCE NanoSmart Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Announces Positive Top-Line Results from XIAFLEX® Multi-Cord Study
2. Omthera Pharmaceuticals, Inc. to Present at the Rodman and Renshaw 13th Annual Healthcare Conference
3. Pacira Pharmaceuticals, Inc. Expands EXPAREL™ Commercial Team Infrastructure
4. Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX®
5. Janssen Pharmaceuticals, Inc. Launches Online Tools on
6. Omthera Pharmaceuticals, Inc. Initiates Phase III ESPRIT Trial of Add-on Epanova™ to Statin Therapy in Patients with Hypertriglyceridemia
7. Pacira Pharmaceuticals, Inc. to Present at Wedbush Securities 2011 Life Sciences Management Access Conference
8. Pacira Pharmaceuticals, Inc. Reports Second Quarter 2011 Financial Results
9. K-V Pharmaceutical Company Announces the Completion of the Sale of Nesher Pharmaceuticals, Inc. its Generic Pharmaceutical Business
10. Auxilium Pharmaceuticals, Inc. Announces Promotion of Dr. James P. Tursi to Chief Medical Officer
11. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2011 Financial Results
Post Your Comments:
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/23/2016)... HILLS, Calif. , June 23, 2016 Any ... the many challenges of the current process. Many of them ... because of the technical difficulties and high laboratory costs involved. ... have to offer it at such a high cost that ... afford it. Dr. Parsa Zadeh , founder ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... ... patient payment industry today announced its strategic partnership with Connance, a healthcare ... , The two companies’ proven, proprietary technology combine to provide health systems, ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a ... can give their videos a whole new perspective by using the title layers ... Film Studios. , ProSlice Levels contains over 30 Different presets to choose from. ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... Austin ... of the American College of Mohs Surgery and to Dr. Russell Peckham for medical ... and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/24/2016)... , ... June 24, 2016 , ... June 19, 2016 ... dangers associated with chronic pain and the benefits of holistic treatments, Serenity Recovery ... are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder ...
Breaking Medicine News(10 mins):